Journal Article DZNE-2025-01160

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
CSF Beta-Synuclein, SNAP-25, and Neurogranin in Infectious and Autoimmune Inflammatory Neurologic Diseases.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Wolters Kluwer Philadelphia, Pa.

Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology 12(6), e200491 () [10.1212/NXI.0000000000200491]

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Beta-synuclein (beta-syn), synaptosomal-associated protein 25 (SNAP-25), and neurogranin are CSF biomarkers of synaptic damage, which have been poorly investigated in non-neurodegenerative neurologic diseases. In this study, we examined the diagnostic and prognostic role of these markers compared with the neuroaxonal damage marker neurofilament light chain protein (NfL) in infectious and autoimmune inflammatory neurologic diseases (IINDs and AINDs).This cohort study included CSF samples from patients with different etiologies of IIND (varicella-zoster virus, herpes simplex virus, tick-borne meningoencephalitis, bacterial meningitis/(meningo)encephalitis, neuroborreliosis, or other/unknown etiology) or AIND (autoimmune encephalitis or other etiology) as well as controls.A total of 123 patients with IINDs (mean age 55.23 ± 18.04 years, 43.2% female), 22 with AINDs (age 60.41 ± 16.03 years, 81.8% female), and 95 controls (age 52.39 ± 17.94 years, 56.9% female) were enrolled. Compared with the control group, participants with IINDs and AINDs showed higher concentrations of beta-syn (p < 0.001 and p = 0.038, respectively), neurogranin (p = 0.039 and p = 0.002, respectively), and NfL (p < 0.001 and p = 0.001, respectively), with no differences between the 2 latter groups. Overall, synaptic markers and NfL demonstrated poor-to-moderate diagnostic accuracy in discriminating between diagnostic groups (area under the curve 0.366-0.809). All synaptic biomarkers were elevated in participants with IINDs presenting with altered mental status (beta-syn, p < 0.001; SNAP-25, p = 0.002; and neurogranin, p = 0.008), seizures (beta-syn, p = 0.013; SNAP-25, p = 0.005; and neurogranin, p = 0.004), and inflammatory changes on neuroimaging (beta-syn, p = 0.016; SNAP-25, p = 0.029; and neurogranin, p = 0.007). Participants with AINDs requiring intensive care showed higher levels of beta-syn (p = 0.033) and NfL (p = 0.002). Participants with IINDs with a poor functional status (modified Rankin Scale [mRS] scores of 3-6) exhibited higher concentrations of beta-syn (p < 0.001), SNAP-25 (p = 0.022), neurogranin (p = 0.004), and NfL (p < 0.001) compared with those with mRS scores of 0-2. Accordingly, higher levels of synaptic markers were associated with poorer short-term outcomes in patients with IINDs, but not in those with AINDs.Elevated CSF levels of beta-syn, neurogranin, and NfL may suggest a common pattern of synaptic and neuroaxonal damage in both IINDs and AINDs. Although these biomarkers have limited value in distinguishing between different diseases, they are associated with clinical severity and with short-term outcome, particularly in patients with IINDs.

Keyword(s): Humans (MeSH) ; Female (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Neurogranin: cerebrospinal fluid (MeSH) ; Aged (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Adult (MeSH) ; Synaptosomal-Associated Protein 25: cerebrospinal fluid (MeSH) ; Autoimmune Diseases of the Nervous System: cerebrospinal fluid (MeSH) ; Autoimmune Diseases of the Nervous System: diagnosis (MeSH) ; Cohort Studies (MeSH) ; Neuroinflammatory Diseases: cerebrospinal fluid (MeSH) ; Neuroinflammatory Diseases: diagnosis (MeSH) ; alpha-Synuclein: cerebrospinal fluid (MeSH) ; Encephalitis: cerebrospinal fluid (MeSH) ; Encephalitis: diagnosis (MeSH) ; Neurofilament Proteins: cerebrospinal fluid (MeSH) ; Neurogranin ; Biomarkers ; Synaptosomal-Associated Protein 25 ; SNAP25 protein, human ; SNCA protein, human ; alpha-Synuclein ; Neurofilament Proteins ; neurofilament protein L

Classification:

Contributing Institute(s):
  1. Translational Mass Spectrometry and Biomarker Research (AG Öckl)
  2. Clinical Study Center (Ulm) (Clinical Study Center (Ulm))
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025
Database coverage:
Medline ; Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 ; DOAJ ; OpenAccess ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > UL DZNE > UL DZNE-Clinical Study Center (Ulm)
Document types > Articles > Journal Article
Institute Collections > UL DZNE > UL DZNE-AG Öckl
Full Text Collection
Public records
Publications Database

 Record created 2025-10-10, last modified 2025-11-03


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)